Quantcast

Latest Andrew Witty Stories

2014-07-23 08:30:55

LONDON, July 23, 2014 /PRNewswire/ -- Global healthcare company GSK reports Q2 results reflecting a business that is facing currency headwinds, increased price competition and supply disruptions to its Consumer business. However its CEO Sir Andrew Witty points out that the company is very much in transition, citing progress in the development pipeline as reason to be confident about long-term prospects as well as the investments being made to drive long-term growth. CFO...

2014-03-18 12:31:39

LONDON, March 18, 2014 /PRNewswire/ -- UK government, leading industrial, investor and academic speakers to review strategies to support the commercialisation of academic research at a new Elsevier conference "Research Commercialisation: From Ideas to IPO": 19-20 May 2014, London, UKhttp://www.idea2ipo-conference.com With high expectations of a return on government and public investment in academic research regarding job creation and economic growth, the pressure...

GSK Stops Paying Docs To Market Meds
2013-12-18 09:15:55

Rebekah Eliason for redOrbit.com – Your Universe Online Amid accusations of bribery and scandal, GlaxoSmithKline (GSK), one of the leading drug makers, will stop paying doctors to promote its drugs and cease targets for number of prescriptions filled for the marketing staff. This is a first for the giant drug company, which has long been fighting scandals over its sales practices. Such a huge step is a major challenge to other drug companies and could force them to follow their example....

GSK Pharma Acquires Human Genome Sciences For $3.6 Billion
2012-07-17 09:45:58

Lawrence LeBlond for redOrbit.com - Your Universe Online British pharmaceutical giant GlaxoSmithKline (GSK) has acquired US-based Human Genome Sciences (HGS) after tough negotiations saw it raise offers from an initial $2.6 billion in April, putting the final value of the deal at $3.6 billion or $14.25 per share. By securing HGS, GSK is gaining full control of the drug Benlysta, the first drug in more than 50 years to be approved by the Food and Drug Administration (FDA) for the...

Pharma Giant Agrees To Pay $3 Billion In Fines For Improper Practices
2012-07-02 19:08:05

Lawrence LeBlond for redOrbit.com - Your Universe Online Pharmaceutical giant GlaxoSmithKline (GSK) pleaded guilty and has agreed to pay the largest fine in US history over charges that it marketed drugs for unauthorized uses, held back safety data, and cheated the government´s Medicaid program, the US Justice Department (DOJ) announced Monday. GSK was also accused of paying kickbacks to doctors, funding expensive trips and other benefits, to gain their support for their drugs....

2011-07-26 07:33:00

LONDON, July 26, 2011 /PRNewswire/ -- UK pharma group GlaxoSmithKline reports a 2% sales dip in the second quarter but highlights strong underlying sales momentum. In an interview with financial broadcaster http://www.cantos.com, CEO Andrew Witty and CFO Simon Dingemans review Q2 results including overall delivery of strategy, declining "headwinds", R&D strategy, improving margins and a review of the recently implemented Drug Performance Units. The interview...

2010-10-13 18:01:00

PHILADELPHIA, Oct. 13 /PRNewswire/ -- At the launch of the World Health Organization's (WHO) first report on Neglected Tropical Diseases today, GSK announced a new five year commitment to expand the donation of its medicine albendazole to treat children at risk of intestinal worms, known as soil-transmitted helminths (STH). Today's report confirms that intestinal worms cause more ill health in school-aged children than any other infection. STHs aggravate malnutrition and amplify rates of...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'